Medical News

RSS

Exelixis reports interim data from XL184 phase 2 trial for recurrent glioblastoma at ASCO 2010

Exelixis, Inc. today reported promising interim data from an ongoing phase 2 trial of XL184 in patients with recurrent glioblastoma (GB), the most common and aggressive form of brain cancer. Dr. Patrick Wen from the Dana Farber Cancer Institute in Boston, MA will present the data in an Oral Session (Abstract #2006) on Saturday, June 5 at 5:00 p.m. at the 2010 Annual Meeting of the American Society of Clinical Oncology in Chicago.

21 May 2010

More than 44% Canadian seniors living in residential care homes diagnosed with depression: CIHI study

More than two in five (44%) Canadian seniors living in residential care homes are diagnosed with or have symptoms of depression, according to a new study released today by the Canadian Institute for Health Information.

21 May 2010

Salix announces additional intellectual property protection for rifaximin in treatment of IBS

Salix Pharmaceuticals, Ltd. today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 7,718,608. This patent provides protection until August 2019 for rifaximin, which Salix markets in the United States under the trade names XIFAXAN® (200mg) and XIFAXAN550™ (550mg).

21 May 2010

Restaurant Health Care Alliance launched to help restaurant employees gain access to health care coverage

The National Restaurant Association and UnitedHealthcare are launching the Restaurant Health Care Alliance, offering a suite of products that will help nearly 13 million restaurant employees gain easier access to health care coverage and related products and services. Today, 4 million to 6 million of the nation's nearly 13 million food service industry employees are uninsured at any given time.

21 May 2010

Phase II study results of Lilly Oncology's tasisulam for metastatic melanoma to be presented at 46th ASCO

Lilly released results today from a Phase II study evaluating Lilly Oncology's tasisulam, a novel anti-cancer agent, in patients with metastatic melanoma, the deadliest form of skin cancer. Study results will be presented during the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) held in Chicago, Ill. on June 6, 2010.

21 May 2010

MSCRF awards grants to 42 projects under Maryland Stem Cell Research Act of 2006

The Maryland Stem Cell Research Commission has completed its evaluation of the 141 applications in response to its three official Requests for Applications during the FY 2010 funding cycle. The board of directors of the Maryland Technology Development Corporation reviewed the Commission's recommendations and approved 42 projects totaling $11.7 million in funding through the Maryland Stem Cell Research Fund under the Maryland Stem Cell Research Act of 2006.

21 May 2010

ZymoGenetics' IL-21 Phase 2 trial data in metastatic melanoma to be presented at ASCO annual meeting

ZymoGenetics, Inc. announced that final progression-free survival results will be presented from a Phase 2 clinical trial in patients with Stage 4 metastatic melanoma at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago on June 5, 2010 in an oral presentation. The open-label multi-center clinical trial evaluated 3 dose regimens of Interleukin 21 (IL-21) in 40 patients with no prior systemic therapy for metastatic melanoma.

21 May 2010

Obesity rate decreases as amount of weekly LTPA increases

It may seem intuitive that greater amounts of exercise lead to less obesity, but an Indiana University study has found that this conventional wisdom applies primarily to white women. The findings draw attention not only to racial, ethnic and gender differences regarding exercise but also to the role work can play.

21 May 2010

Positive results from Phase 1 study evaluating IV administration of JX-594 to metastatic cancer patients

Jennerex, Inc., a clinical-stage cancer biotherapeutics company, today reported positive results from its Phase 1 dose escalation study evaluating the intravenous administration of JX-594 to patients with metastatic cancer. The data presented today demonstrated clear dose-related delivery to solid tumors, cancer-targeted replication and gene expression, and anti-cancer effects of JX-594 delivered IV.

21 May 2010

JCVI researchers construct first self-replicating, synthetic bacterial cell

Researchers at the J. Craig Venter Institute (JCVI), a not-for-profit genomic research organization, published results today describing the successful construction of the first self-replicating, synthetic bacterial cell. The team synthesized the 1.08 million base pair chromosome of a modified Mycoplasma mycoides genome.

21 May 2010

Hepatitis C affects so many people and yet not recognized as serious public health problem

May is Hepatitis Awareness Month, and you may find it surprising to learn an estimated 4 million Americans have been infected with Hepatitis C. This silent disease is three to five times more prevalent than HIV. Hepatitis C is the most common cause of liver transplants in the U.S.

21 May 2010

HemaCare announces commercial cell therapy collection agreement with Dendreon

HemaCare Corporation today announced an agreement with Dendreon Corporation to provide cellular collection services in Los Angeles and Maine for their new autologous cellular immunotherapy, PROVENGE® (sipuleucel-T). This personalized medicine is Dendreon's lead product and is the first autologous cellular immunotherapy specifically designed to engage patients' own immune systems to treat cancer.

21 May 2010

Experts to discuss impacts of air pollution on life expectancy, cardiovascular disease

The U.S. Environmental Protection Agency is sponsoring a seminar called "Breathe Cleaner, Live Longer: Understanding Air Pollution after 40 Years." The event is co-sponsored by the American Heart Association and the U.S. House of Representatives Committee on Science and Technology.

21 May 2010

Toxcure granted U.S. patent for method of treating neoplasms with neurotoxins

Toxcure, LLC, an emerging specialty biopharmaceutical company, today announced the grant of U.S. Patent No. 7,709,440, which provides Toxcure with intellectual property protection for a method of treating various tumors with neurotoxins.

21 May 2010

Data from Phase 3 clinical trials of PROVENGE in advanced prostate cancer to be presented at ASCO 2010

Dendreon Corporation today announced the upcoming presentation of data from integrated analyses of three Phase 3 PROVENGE (sipuleucel-T) clinical trials of an autologous cellular immunotherapy in advanced prostate cancer, to be presented at the annual meeting of the American Society of Clinical Oncology in Chicago on Monday, June 7 at 8:00 a.m. CT.

21 May 2010

Caregivers can give complete clinical picture of brain cancer patients' condition

Despite grim prognoses and aggressive treatments, cancer patients suffering from malignant gliomas -- primary brain tumors -- often rate their quality of life more optimistically than their caregivers do, according to a new Northwestern University Feinberg School of Medicine study.

21 May 2010

SLU Hospital announces increase in number of minimally-invasive spinal procedures performed

With the recent launch of the Neurosurgical Spine Program at Saint Louis University Hospital's Center for Cerebrovascular and Skull Base Surgery, the hospital has seen a dramatic increase in the number of minimally-invasive spinal procedures, including lumbar spinal fusion surgery. Designed to stop the motion at a painful vertebral segment, this procedure is traditionally performed via a large incision on the back, stripping vital muscles away from the spine. However, the emergence of minimally-invasive neurosurgical techniques is revolutionizing spinal surgery.

21 May 2010

Preliminary data of BIBW 2992 in head and neck cancer, NSCLC to be presented at ASCO 2010

Boehringer Ingelheim will announce preliminary data in the areas of head and neck cancer and non-small cell lung cancer for one of the company's investigational compounds, BIBW 2992. These data will be presented at the 2010 Annual Meeting of the American Society of Clinical Oncology annual meeting in Chicago.

21 May 2010

Medtronic announces clinical data presentations on cardiovascular devices at EuroPCR

Medtronic, Inc., announced today the schedule of important clinical data presentations during EuroPCR, a major cardiology meeting taking place May 25-28 in Paris at the Palais de Congrès.

21 May 2010

Onyx Pharmaceuticals announces presentations evaluating carfilzomib for multiple myeloma at 46th ASCO

Onyx Pharmaceuticals, Inc. today announced the presentation of several studies evaluating carfilzomib, a selective, next-generation proteasome inhibitor, at the 46th American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8, 2010 in Chicago, IL.

21 May 2010

Medical News

Exelixis reports interim data from XL184 phase 2 trial for recurrent glioblastoma at ASCO 2010

More than 44% Canadian seniors living in residential care homes diagnosed with depression: CIHI study

Salix announces additional intellectual property protection for rifaximin in treatment of IBS

Restaurant Health Care Alliance launched to help restaurant employees gain access to health care coverage

Phase II study results of Lilly Oncology's tasisulam for metastatic melanoma to be presented at 46th ASCO

MSCRF awards grants to 42 projects under Maryland Stem Cell Research Act of 2006

ZymoGenetics' IL-21 Phase 2 trial data in metastatic melanoma to be presented at ASCO annual meeting

Obesity rate decreases as amount of weekly LTPA increases

Positive results from Phase 1 study evaluating IV administration of JX-594 to metastatic cancer patients

JCVI researchers construct first self-replicating, synthetic bacterial cell

Hepatitis C affects so many people and yet not recognized as serious public health problem

HemaCare announces commercial cell therapy collection agreement with Dendreon

Experts to discuss impacts of air pollution on life expectancy, cardiovascular disease

Toxcure granted U.S. patent for method of treating neoplasms with neurotoxins

Data from Phase 3 clinical trials of PROVENGE in advanced prostate cancer to be presented at ASCO 2010

Caregivers can give complete clinical picture of brain cancer patients' condition

SLU Hospital announces increase in number of minimally-invasive spinal procedures performed

Preliminary data of BIBW 2992 in head and neck cancer, NSCLC to be presented at ASCO 2010

Medtronic announces clinical data presentations on cardiovascular devices at EuroPCR

Onyx Pharmaceuticals announces presentations evaluating carfilzomib for multiple myeloma at 46th ASCO

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Latest News